
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is a biotech company with a strong pipeline and promising lead drugs targeting CNS tumors. With potential market entries in 2030 and 2031 and key catalysts expected in 2026 and 2027, the company has a solid outlook for growth. Additionally, their multiple patents and valuation based on a DCF analysis further support a positive outlook for investors.
Bears say
NeOnc Technologies Hldgs is a clinical-stage biopharmaceutical company focused on developing novel drug delivery technologies and treatments for central nervous system diseases, with a focus on intracranial malignancies. However, the company faces significant competitive, commercial, and political risks, and their lead product candidates are not expected to have phase II clinical data until 2026. Additionally, the company's potential pivotal trial and its mechanism of action rely on still unproven assumptions about drug activity, and the company's leadership has a relatively short track record in the industry.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares